Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Double Negative T Cell: “Off-the-Shelf” Allogeneic CAR T Cell Platform for T Cell Malignancies
FY 2020-21
Summary
Using double negative T cells in immunotherapy for T cell acute lymphoblastic leukemia T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer of the immune cells. Current treatment involves combination chemotherapy; however, 20-40% of patients relapse with limited recourse. Recently, a form of immunotherapy, called chimeric antigen receptor (CAR)-T cell therapy, has shown clinical success in certain leukemias. In current CAR-T cell therapy, T cells from patients are genetically modified to target and kill cancer cells. However, its application to T-ALL is currently limited due to several challenges. Since leukemic and CAR-T cells share the many targetable molecules, CAR-T cells that target leukemic cells also kill other CAR-T cells. Moreover, it is difficult to isolate enough number of healthy cells from T-ALL patients for CAR-T cell manufacturing. Alternatively, T cells from healthy donors can be used, but the donor's immune cells can mistakenly attack the recipient's normal cells. This study aims to circumvent these challenges by employing a type of unconventional T cells, called double negative T (DNT) cells. Unlike conventional T cells, DNT cells do not express certain surface molecules typically found on T-ALL, meaning that they can be modified to target leukemic T cells without the risk of self-killing. Further, donor-derived DNT cells have shown not to attack normal cells of recipients. Importantly, our preliminary data show that DNT cells can undergo genetic modifications to target T-ALL and increase their anti-cancer function. This study will examine the specificity, safety, and efficacy of CAR-DNT cells against T-ALL in cell culture and animal models. The findings may provide a feasible approach to CAR-T cell therapy for relapsing T-ALL patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449714
Name
Fang Karen Kai-Lin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Double Negative T Cell: “Off-the-Shelf” Allogeneic CAR T Cell Platform for T Cell Malignancies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Car T Cell Therapy; Double Negative T Cells; Immunotherapy; T Cell Acute Lymphoblastic Leukemia
Abstract
Using double negative T cells in immunotherapy for T cell acute lymphoblastic leukemia T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer of the immune cells. Current treatment involves combination chemotherapy; however, 20-40% of patients relapse with limited recourse. Recently, a form of immunotherapy, called chimeric antigen receptor (CAR)-T cell therapy, has shown clinical success in certain leukemias. In current CAR-T cell therapy, T cells from patients are genetically modified to target and kill cancer cells. However, its application to T-ALL is currently limited due to several challenges. Since leukemic and CAR-T cells share the many targetable molecules, CAR-T cells that target leukemic cells also kill other CAR-T cells. Moreover, it is difficult to isolate enough number of healthy cells from T-ALL patients for CAR-T cell manufacturing. Alternatively, T cells from healthy donors can be used, but the donor's immune cells can mistakenly attack the recipient's normal cells. This study aims to circumvent these challenges by employing a type of unconventional T cells, called double negative T (DNT) cells. Unlike conventional T cells, DNT cells do not express certain surface molecules typically found on T-ALL, meaning that they can be modified to target leukemic T cells without the risk of self-killing. Further, donor-derived DNT cells have shown not to attack normal cells of recipients. Importantly, our preliminary data show that DNT cells can undergo genetic modifications to target T-ALL and increase their anti-cancer function. This study will examine the specificity, safety, and efficacy of CAR-DNT cells against T-ALL in cell culture and animal models. The findings may provide a feasible approach to CAR-T cell therapy for relapsing T-ALL patients.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fang, Karen Kai-Lin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~